TY - JOUR
T1 - Semaglutide for cardiovascular event reduction in people with overweight or obesity
T2 - SELECT study baseline characteristics
AU - Lingvay, Ildiko
AU - Brown-Frandsen, Kirstine
AU - Colhoun, Helen M.
AU - Deanfield, John
AU - Emerson, Scott S.
AU - Esbjerg, Sille
AU - Hardt-Lindberg, S. ren
AU - Hovingh, G. Kees
AU - Kahn, Steven E.
AU - Kushner, Robert F.
AU - Lincoff, A. Michael
AU - Marso, Steven P.
AU - Fries, Tea Monk
AU - Plutzky, Jorge
AU - the SELECT Study Group
AU - Ryan, Donna H.
N1 - Funding Information: The authors would like to thank the participants in this trial and the investigators, coordinators, and trial site staff. The authors would also like to thank Tugce Kalayci Oral of Novo Nordisk for critically reviewing the manuscript. Editorial assistance (which included formatting of the manuscript, as well as accuracy checks of data and references), under the direction of Dr. Lingvay, was provided by Lauren McNally and Beth Degg of Axis, a division of Spirit Medical Communications Group Ltd (funded by the sponsor). The authors are grateful for this assistance. Publisher Copyright: © 2022 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Objective: This paper describes the baseline characteristics of the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the largest cardiovascular (CV) outcome studies in the field of obesity, which evaluates the effect of semaglutide versus placebo on major CV events. Methods: SELECT enrolled individuals with overweight or obesity without diabetes, with prior myocardial infarction, stroke, and/or peripheral artery disease. This study reports participants' baseline characteristics in the full study population and subgroups defined by baseline glycated hemoglobin (HbA1c; <5.7%, ≥5.7 to <6.0%, ≥6.0 to <6.5%), baseline waist to height ratio tertile, and qualifying prior CV event or condition. Results: The study enrolled 17,605 participants (72.5% male) with an average (SD) age of 61.6 (8.9) years and BMI of 33.34 (5.04) kg/m2. The most common prior CV event was myocardial infarction (76.3% of participants), followed by stroke (23.3%) and peripheral artery disease (8.6%). Furthermore, 24.3% had a heart failure diagnosis. Two-thirds of participants (66%) had HbA1c in the prediabetes range (5.7%-6.4%). Across groups of increasing HbA1c, prevalence of all CV risk factors increased. Conclusions: The enrolled population in SELECT includes participants across a broad range of relevant risk categories. This will allow the study to garner information about the CV benefits of semaglutide across these relevant clinical subgroups.
AB - Objective: This paper describes the baseline characteristics of the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the largest cardiovascular (CV) outcome studies in the field of obesity, which evaluates the effect of semaglutide versus placebo on major CV events. Methods: SELECT enrolled individuals with overweight or obesity without diabetes, with prior myocardial infarction, stroke, and/or peripheral artery disease. This study reports participants' baseline characteristics in the full study population and subgroups defined by baseline glycated hemoglobin (HbA1c; <5.7%, ≥5.7 to <6.0%, ≥6.0 to <6.5%), baseline waist to height ratio tertile, and qualifying prior CV event or condition. Results: The study enrolled 17,605 participants (72.5% male) with an average (SD) age of 61.6 (8.9) years and BMI of 33.34 (5.04) kg/m2. The most common prior CV event was myocardial infarction (76.3% of participants), followed by stroke (23.3%) and peripheral artery disease (8.6%). Furthermore, 24.3% had a heart failure diagnosis. Two-thirds of participants (66%) had HbA1c in the prediabetes range (5.7%-6.4%). Across groups of increasing HbA1c, prevalence of all CV risk factors increased. Conclusions: The enrolled population in SELECT includes participants across a broad range of relevant risk categories. This will allow the study to garner information about the CV benefits of semaglutide across these relevant clinical subgroups.
UR - http://www.scopus.com/inward/record.url?scp=85144072824&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/oby.23621
DO - https://doi.org/10.1002/oby.23621
M3 - Article
C2 - 36502289
SN - 1930-7381
VL - 31
SP - 111
EP - 122
JO - Obesity
JF - Obesity
IS - 1
ER -